EFECTO DEL USO DE ÁCIDO TRANEXÁMICO EN EL TRATAMIENTO DE MELASMA

Abstract

This study aimed to investigate the efficacy of tranexamic acid (TXA) in the treatment of melasma, a skin condition that poses challenges due to its chronic nature and variable response to conventional therapies. Methodology: A systematic review of randomized clinical trials was conducted to evaluate the efficacy of tranexamic acid (TXA) in the treatment of melasma. The literature search covered studies from 2019 to October 2023 in various electronic databases. Studies that met strict inclusion criteria were selected, prioritizing controlled and randomized clinical trials. The safety and efficacy of TXA in various formulations and routes of administration, such as oral, transepidermal, and intradermal, were evaluated. Results: The findings demonstrated that TXA, in its different forms of administration, led to a reduction in the Melasma Area and Severity Index (MASI) scores, indicating improvements in skin pigmentation and dermal microcirculation. Reductions in epidermal melanin density and the number of pendulous melanocytes were observed. Additionally, the efficacy of TXA combined with other therapeutic agents, such as ascorbic acid or platelet-rich plasma, to improve melasma was highlighted. Conclusion: TXA emerges as an effective therapeutic option in the treatment of melasma. Its ability to improve MASI scores suggests a positive effect on skin pigmentation and dermal microcirculation. However, challenges such as treatment tolerability and recurrence rates persist.